Patents by Inventor Ruud Albers
Ruud Albers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240122961Abstract: The invention relates to a prebiotic composition for use in a method of therapeutic or prophylactic treatment of disorders associated with disturbed composition or functionality of the intestinal microbiome in a subject, said use comprising oral administration of the prebiotic composition to the subject, wherein the composition contains at least 0.1% by weight of dry matter of RG-I polysaccharides originating from fruit, carrot, pea, chicory or sugar beet, said RG-I polysaccharides having a molecular weight in excess of 15 kDa and having a backbone consisting of galacturonic acid residues and rhamnose residues, said rhamnose residues being contained in alpha(1?4)-galacturonic-alpha(1?2)-rhamnose residues, wherein the molar ratio of galacturonic acid residues to rhamnose residues in the RG-I polysaccharides is within the range of 20:1 to 1:1.Type: ApplicationFiled: July 24, 2023Publication date: April 18, 2024Applicant: NutriLeads B.V.Inventors: Ruud ALBERS, Maria TZOUMAKI
-
Patent number: 11723915Abstract: The invention relates to a product for use in the therapeutic or prophylactic treatment of infections, said treatment comprising oral administration of the product, wherein the product is selected from a nutritional formulation, a food product, a dietary supplement, a beverage and a pharmaceutical product, said product containing carrot RG-I polysaccharides having the following combination features: a molecular weight in the range 10-300 kDa; a backbone consisting of galacturonic acid residues and rhamnose residues, said rhamnose residues being contained in alpha(1?4)-galacturonic-alpha(1?2)-rhamnose residues; the following monosaccharide composition: 20-60 mol. % galacturonic acid residues, wherein the individual galacturonic acids can be methylated and/or acetyl-esterified; 8-50 mol. % rhamnose residues; 0-40 mol. % arabinose residues; 0-40 mol.Type: GrantFiled: April 22, 2020Date of Patent: August 15, 2023Assignee: NutriLeads B.V.Inventors: Ruud Albers, Maria Tzoumaki
-
Patent number: 11524025Abstract: The invention relates to a composition for use in the prevention or treatment of Salmonellosis in animals, said use comprising administering the composition to the animal, wherein the composition contains at least 0.01% by weight of dry matter of rhamnogalacturonan I (RG-I) polysaccharides having a molecular weight of more than 2 kDa and having a backbone consisting of galacturonic acid residues and rhamnose residues, said rhamnose residues being contained in alpha(1?4)-galacturonic-alpha(1?2)-rhamnose residues, wherein the molar ratio of galacturonic acid residues to rhamnose residues in the RG-I polysaccharides is within the range of 50:1 to 1:1. The use of RG-I polysaccharides in the treatment or prevention of Salmonellosis provides an alternative for the widespread use of antibiotics. Furthermore, these RG-I polysaccharides may be used to prevent or treat Salmonellosis caused by Salmonella strains with resistance to antibiotics.Type: GrantFiled: June 1, 2020Date of Patent: December 13, 2022Assignee: NutriLeads B.V.Inventors: Maria Tzoumaki, Ruud Albers
-
Publication number: 20210177886Abstract: The invention relates to a prebiotic composition for use in a method of therapeutic or prophylactic treatment of disorders associated with disturbed composition or functionality of the intestinal microbiome in a subject, said use comprising oral administration of the prebiotic composition to the subject, wherein the composition contains at least 0.1% by weight of dry matter of RG-I polysaccharides originating from fruit, carrot, pea, chicory or sugar beet, said RG-I polysaccharides having a molecular weight in excess of 15 kDa and having a backbone consisting of galacturonic acid residues and rhamnose residues, said rhamnose residues being contained in alpha(1?4)-galacturonic-alpha(1?2)-rhamnose residues, wherein the molar ratio of galacturonic acid residues to rhamnose residues in the RG-I polysaccharides is within the range of 20:1 to 1:1.Type: ApplicationFiled: February 24, 2021Publication date: June 17, 2021Inventors: Ruud ALBERS, Maria TZOUMAKI
-
Publication number: 20200289545Abstract: The invention relates to a composition for use in the prevention or treatment of Salmonellosis in animals, said use comprising administering the composition to the animal, wherein the composition contains at least 0.01% by weight of dry matter of rhamnogalacturonan I (RG-I) polysaccharides having a molecular weight of more than 2 kDa and having a backbone consisting of galacturonic acid residues and rhamnose residues, said rhamnose residues being contained in alpha(1?4)-galacturonic-alpha(1?2)-rhamnose residues, wherein the molar ratio of galacturonic acid residues to rhamnose residues in the RG-I polysaccharides is within the range of 50:1 to 1:1. The use of RG-I polysaccharides in the treatment or prevention of Salmonellosis provides an alternative for the widespread use of antibiotics. Furthermore, these RG-I polysaccharides may be used to prevent or treat Salmonellosis caused by Salmonella strains with resistance to antibiotics.Type: ApplicationFiled: June 1, 2020Publication date: September 17, 2020Inventors: Maria TZOUMAKI, Ruud ALBERS
-
Publication number: 20200246373Abstract: The invention relates to a product for use in the therapeutic or prophylactic treatment of infections, said treatment comprising oral administration of the product, wherein the product is selected from a nutritional formulation, a food product, a dietary supplement, a beverage and a pharmaceutical product, said product containing carrot RG-I polysaccharides having the following combination features: a molecular weight in the range 10-300 kDa; a backbone consisting of galacturonic acid residues and rhamnose residues, said rhamnose residues being contained in alpha(1?4)-galacturonic-alpha(1?2)-rhamnose residues; the following monosaccharide composition: 20-60 mol. % galacturonic acid residues, wherein the individual galacturonic acids can be methylated and/or acetyl-esterified; 8-50 mol. % rhamnose residues; 0-40 mol. % arabinose residues; 0-40 mol.Type: ApplicationFiled: April 22, 2020Publication date: August 6, 2020Inventors: Ruud ALBERS, Maria TZOUMAKI
-
Publication number: 20200247912Abstract: The invention provides a method of producing a hydrolysed pectic polysaccharide isolate that is enriched in rhamnogalacturonan-I, said method comprising the steps of: providing a pectin-rich substrate that has been obtained from plant material without the use of organic solvent, said pectin-rich substrate containing at least 3% by weight of dry matter of pectic polysaccharides; subjecting the pectin-rich substrate to enzymatic treatment to partially hydrolyse the pectic polysaccharides, said treatment enzymatic treatment comprising the use of one or more pectinases selected from pectin lyase (EC4.2.2.10), pectate lyase (EC 4.2.2.2), rhamnogalacturonan galacturonohydrolase (EC 3.2.1.173), endo-polygalacturonase (EC 3.2.1.15), exopolygalacturonase (EC 3.2.1.67 and EC 3.2.1.82); subjecting the partially hydrolysed pectic polysaccharides to ultrafiltration using an ultrafiltration membrane having a molecular weight cut-off in the range of 5 to 100 kDa; and recovering the ultrafiltration retentate.Type: ApplicationFiled: April 22, 2020Publication date: August 6, 2020Inventors: Ruud ALBERS, Maria TZOUMAKI
-
Patent number: 10449249Abstract: Objective of the present invention is to provide polysaccharides which modulate immune response, and which can be used as ingredients in edible products or pharmaceutical compositions. The present invention provides such polysaccharides obtained from the species Camellia sinensis, which comprise a rhamnogalacturonan-I core, and wherein the molar ratio of galacturonyl acid residues to rhamnosyl residues in the backbone of the polysaccharide is close to 1:1. The present invention also provides edible products or pharmaceutical compositions containing such polysaccharides, in order to modulate immune response.Type: GrantFiled: August 3, 2018Date of Patent: October 22, 2019Assignee: NUTRILEADS B.V.Inventors: Ruud Albers, Jari Helin, Werner Klaffke, Jean Hypolites Koek, Petronella Anna Kreijveld, Jari Natunen, Erwin Werner Tareilus, Richardus Paulus Anton Oranje
-
Publication number: 20180339040Abstract: Objective of the present invention is to provide polysaccharides which modulate immune response, and which can be used as ingredients in edible products or pharmaceutical compositions. The present invention provides such polysaccharides obtained from the species Camellia sinensis, which comprise a rhamnogalacturonan-I core, and wherein the molar ratio of galacturonyl acid residues to rhamnosyl residues in the backbone of the polysaccharide is close to 1:1. The present invention also provides edible products or pharmaceutical compositions containing such polysaccharides, in order to modulate immune response.Type: ApplicationFiled: August 3, 2018Publication date: November 29, 2018Inventors: Ruud ALBERS, Jari HELIN, Werner KLAFFKE, Jean Hypolites KOEK, Petronella Anna KREIJVELD, Jari NATUNEN, Erwin Werner TAREILUS, Richardus Paulus Anton ORANJE
-
Patent number: 10098948Abstract: Objective of the present invention is to provide polysaccharides which modulate immune response, and which can be used as ingredients in edible products or pharmaceutical compositions. The present invention provides such polysaccharides obtained from the species Camellia sinensis, which comprise a rhamnogalacturonan-I core, and wherein the molar ratio of galacturonyl acid residues to rhamnosyl residues in the backbone of the polysaccharide is close to 1:1. The present invention also provides edible products or pharmaceutical compositions containing such polysaccharides, in order to modulate immune response.Type: GrantFiled: February 8, 2016Date of Patent: October 16, 2018Assignee: NUTRILEADS B.V.Inventors: Ruud Albers, Jari Helin, Werner Klaffke, Jean Hypolites Koek, Petronella Anna Kreijveld, Jari Natunen, Erwin Werner Tareilus, Richardus Paulus Anton Oranje
-
Publication number: 20160151485Abstract: Objective of the present invention is to provide polysaccharides which modulate immune response, and which can be used as ingredients in edible products or pharmaceutical compositions. The present invention provides such polysaccharides obtained from the species Camellia sinensis, which comprise a rhamnogalacturonan-I core, and wherein the molar ratio of galacturonyl acid residues to rhamnosyl residues in the backbone of the polysaccharide is close to 1:1. The present invention also provides edible products or pharmaceutical compositions containing such polysaccharides, in order to modulate immune response.Type: ApplicationFiled: February 8, 2016Publication date: June 2, 2016Applicant: NutriLeads B.V.Inventors: Ruud ALBERS, Jari HELIN, Werner KLAFFKE, Jean Hypolites KOEK, Petronella Anna KREIJVELD, Jari NATUNEN, Erwin Werner TAREILUS, Richardus Paulus Anton ORANJE
-
Patent number: 9260535Abstract: Objective of the present invention is to provide polysaccharides which modulate immune response, and which can be used as ingredients in edible products or pharmaceutical compositions. The present invention provides such polysaccharides obtained from the species Camellia sinensis, which comprise a rhamnogalacturonan-I core, and wherein the molar ratio of galacturonyl acid residues to rhamnosyl residues in the backbone of the polysaccharide is close to 1:1. The present invention also provides edible products or pharmaceutical compositions containing such polysaccharides, in order to modulate immune response.Type: GrantFiled: November 16, 2010Date of Patent: February 16, 2016Assignee: NutriLeads B.V.Inventors: Ruud Albers, Jari Helin, Werner Klaffke, Jean Hypolites Koek, Petronella Anna Kreijveld, Jari Natunen, Erwin Werner Tareilus, Richardus Paulus Anton Oranje
-
Publication number: 20130064858Abstract: Objective of the present invention is to provide polysaccharides which modulate immune response, and which can be used as ingredients in edible products or pharmaceutical compositions. The present invention provides such polysaccharides obtained from the species Camellia sinensis, which comprise a rhamnogalacturonan-I core, and wherein the molar ratio of galacturonyl acid residues to rhamnosyl residues in the backbone of the polysaccharide is close to 1:1. The present invention also provides edible products or pharmaceutical compositions containing such polysaccharides, in order to modulate immune response.Type: ApplicationFiled: November 16, 2010Publication date: March 14, 2013Inventors: Ruud Albers, Jari Helin, Werner Klaffke, Jean Hypolites Koek, Petronella Anna Kreijveld, Jari Natunen, Erwin Werner Tareilus, Richardus Paulus Anton Oranje
-
Patent number: 8309075Abstract: One aspect of the present invention relates to an edible product containing: • probiotic bacteria in an amount of at least 103 bacteria per gram; and • at least 0.5 mg/g of ginseng polysaccharides containing at least 2 monosaccharide units, preferably at least 4 monosaccharide units. Another aspect of the invention relates to the use of the aforementioned product in therapeutic and prophylactic treatments. The present invention further provides a method of producing a packaged liquid edible product containing probiotic bacteria and ginseng polysaccharides in the aforementioned amounts.Type: GrantFiled: October 26, 2006Date of Patent: November 13, 2012Assignee: NutrileadsInventors: Ruud Albers, Wilhelmina Martina Blom, Adrianus Marinus Ledeboer, Ingrid Celestina Mohede, Jan Willem Sanders
-
Publication number: 20090269307Abstract: One aspect of the present invention relates to an edible product containing: • probiotic bacteria in an amount of at least 103 bacteria per gram; and • at least 0.5 mg/g of ginseng polysaccharides containing at least 2 monosaccharide units, preferably at least 4 monosaccharide units. Another aspect of the invention relates to the use of the aforementioned product in therapeutic and prophylactic treatments. The present invention further provides a method of producing a packaged liquid edible product containing probiotic bacteria and ginseng polysaccharides in the aforementioned amounts.Type: ApplicationFiled: October 26, 2006Publication date: October 29, 2009Inventors: Ruud Albers, Wilhelmina Martina Blom, Adrianus Marinus Ledeboer, Ingrid Celestina Mohede, Jan Willem Sanders
-
Publication number: 20090123608Abstract: The present invention provides a method of preparing an edible product comprising non-viable moulds and/or yeasts that are substantially structurally intact and which provide a health benefit, the method comprising subjecting viable moulds and/or yeasts to at least two sub-lethal treatments to obtain the non-viable moulds and/or yeasts providing a health benefit, each sub-lethal treatment on its own not being sufficient to render the moulds and/or yeasts non-viable.Type: ApplicationFiled: June 27, 2006Publication date: May 14, 2009Inventors: Ruud Albers, Adrianus Marinus Ledeboer, Stanley Brul
-
Publication number: 20090035288Abstract: The present invention provides a method of preparing an edible product comprising non-viable bacteria providing a health benefit, the method comprising subjecting viable bacteria to at least two sub-lethal treatments to obtain the non-viable bacteria providing a health benefit, each sub-lethal treatment on its own not being sufficient to render the bacteria non-viable. The method porvides non-viable bacteria providing health benefits but which can conveniently be incorporated into a range of edible products.Type: ApplicationFiled: June 29, 2006Publication date: February 5, 2009Inventors: Ruud Albers, Stanley Brul, Adrianus Marinus Ledeboer, Willem Maarten Meijer